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Abstract The typical presentation of early stage lung
cancers on low-dose CT screening are non-calcified pul-
monary nodules. However, there is a wide spectrum of
unusual focal abnormalities that can be early presenta-
tions of lung cancer. These abnormalities include, for
example, cancers associated with ‘cystic airspaces’ or
scar-like cancers. The detection of lung cancer with
low-dose CT can be affected by the absence of intrave-
nous contrast medium. As a consequence, endobronchial
and central lesions can be difficult to recognize, raising
the potential for missed cancers. Focal lesions arising
within pre-existing lung disease, such as lung fibrosis
or apical scars, can also be early lung cancer manifes-
tations and deserve particular consideration as recogni-
tion of these lesions may be hindered by the underlying
disease. Furthermore, the unpredictable growth rate of
lung cancer, which ranges from indolent to aggressive
cancers, necessitates attention to the wide spectrum of
progression in lung cancer appearance on serial low-
dose CT scans. In this pictorial review we discuss the
spectrum of early lung cancer presentation in low-dose
CT screening, highlighting typical as well as unusual
radiological features and the varied growth rates of ear-
ly lung cancer.
Teaching Points
• There is a wide spectrum of early presentations of lung
cancer on LDCT.
• Low radiation dose and the absence of contrast medium
injection can affect lung cancer detection.
• Lung cancer growth shows various behaviours, ranging
from indolent to aggressive cancers.
• Familiarity with LDCT technique can improve CTscreening
effectiveness and avoid missed diagnosis.
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Introduction
Lung cancer is the most commonly diagnosed cancer, and was
the leading cause of cancer death globally in males in 2008;
among females, it was the fourth most commonly diagnosed
cancer and the second leading cause of cancer death [1].
The National Lung Cancer Screening Trial (NLST) has
recently demonstrated that low-dose computed tomography
(LDCT) reduces lung cancer mortality by 20 % in high-risk
subjects compared to chest X-ray screening [2]. Based on this
result, LDCT screening of heavy smokers has recently been
recommended by the major American and European scientific
societies [3–6].
LDCT of the lung would seem to be a simple radiological
interpretation but the absence of contrast material injection
and low signal-to-noise ratio due to the low radiation exposure
can lead to misinterpretation and missed significant findings.
Moreover, the distinction between different types of pul-
monary nodules, awareness of the behaviours of early stage
lung cancer and the interpretation of serial LDCT scans are
fundamental in the management of the findings.
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In this pictorial review, we discuss the wide spectrum of
early LDCT findings in lung cancer screening, highlighting
typical as well as unusual radiological features and the varied
growth rates of early stage lung cancer.
Low-dose CT protocol
LDCT for screening purposes is an unenhanced, single breath-
hold scan, conducted from the lung apices through the lung
bases.
Low-dose protocols of the chest can be achievable due to a
high contrast resolution between the air and lung nodules,
gaining a low radiation dose while maintaining good diagnos-
tic quality.
There is no consensus on which level of dose is considered
a ‘low-dose’CT, however, the major screening trials used tube
voltages between 90 kVp and 140 kVp and tube current in the
range of 30–80mAs [7]. Both parameters should be combined
to obtain an acceptable radiation dose, taking into account the
patient’s body habitus and age. The American College of
Radiology (ACR), suggest a CTDIvol ≤3 mGy for standard
size patients [8] while an NLST study concluded that accept-
able CT screening can be accomplished at an overall average
effective dose of approximately 2 mSv [9]. The National
Comprehensive Cancer Care Network guidelines have sug-
gested an effective dose of ≤3 mSv for patients with a body
mass index (BMI) ≤30 kg/m2 and ≤5 mSv for patients with a
BMI >30 kg/m2 [10].
A gantry rotation time of <0.5 seconds is recommended by
the ACR [8]: faster rotation is associated with fewer motion
artifacts and a decreased radiation dose to the patient.
LDCT collimation should be set with the purpose of
achieving thin-section reconstruction images, of at
least ≤1.5 mm [8]. Thin-section images are essential in reading
and interpretation of low-dose CT scans, allowing the use of a
CAD system, volumetric analysis and a more accurate evalu-
ation of subsolid nodules.
Most LDCT screening studies have used the filtered back
projection technique for image reconstruction; nevertheless,
iterative reconstruction algorithms have been shown to im-
prove image quality while reducing radiation dose [11–13].
Recent studies have shown that iterative reconstruction algo-
rithms allow the use of low-dose CT and ultra-low-dose CT
with acceptable image quality [14, 15] and that the detection of
subsolid nodules is not affected by such algorithms [14, 16].
Various methods and tools are available in reporting chest
low-dose CT. Beside the evaluation of axial thin-section im-
ages, the detection rate of pulmonary nodules can be improved
using maximum intensity projection (MIP) which consists of
projecting the voxel with the highest attenuation value on
every view throughout the volume onto a 2D image.
Bastarrika et al. [17] showed that non-overlapping, 10-mm-
thick axial MIP reconstructions enabled more accurate
detection of pulmonary nodules in comparison with 1.25-
mm conventional axial images. Furthermore, Jankowski
et al. evaluated the diagnostic benefits of a MIP and CAD
system for pulmonary nodule detection compared with 1-
mm LDCT images and found that MIP and CAD reduced
the number of overlooked nodules [18]. Also, multiplanar
reconstruction images (MPR) were shown to be a sensitive
technique in lung nodule detection [19], which can be partic-
ularly useful for evaluation of lung hilum and apex.
The use of CAD systems can improve radiologists detec-
tion rate for small pulmonary nodules [20]. The accuracy of
CAD for nodule detection increases with thinner reconstruc-
tion images and with overlapping reconstructed sections [21],
even if this causes an increasing number of false-positive
results.
However, to date, there is no consensus on the optimal
reading technique; further investigations are needed to assess
which method should be used to improve the detection rate of
pulmonary nodules on low-dose CT.
Lung cancer presenting as lung nodules
Low-dose CT can identify small pulmonary nodules in heavy
smokers and thus improve the detection of lung cancer at an
earlier and potentially more curable stage [22, 23]. Non-
calcified pulmonary nodules are the typical presentation of
screen-detected lung cancers on low-dose CT. Based on the
definition of the Fleischner Society [24], the pulmonary nod-
ule is a rounded or irregular opacity, well or poorly defined,
measuring up to 3 cm in diameter.
According to their attenuation, lung nodules can be classi-
fied as solid or subsolid, the latter further divided into part-
solid or non-solid nodules [25].
The spectrum of early stage lung cancer presentation at
low-dose CT includes solid nodules as well as part-solid nod-
ules and ground-glass nodules (Fig. 1).
A pulmonary nodule is defined as solid when it completely
obscures the entire lung parenchyma within it. Non-solid nod-
ules, or pure ground-glass nodules (pGGN), are defined as
focal nodular areas of increased attenuation through which
lung parenchymal structures, such as the pulmonary vessels
or airway structures, can be visualized. Part-solid nodules are
those having both ground-glass and solid components.
Lung nodule attenuation is, therefore, a key feature in lung
cancer screening, with particular emphasis on subsolid nod-
ules. Subsolid nodules are complex lesions both for interpre-
tation and management, and recently the Fleischner society
has published recommendations for their management [26].
Of subsolid nodules, 40–70 % resolve spontaneously in 3
months and, upon resolution, are presumed to have been be-
nign [27]. Part-solid nodules that persist at 3-month follow-up
should be considered potentially malignant: in the ELCAP
study, after adjusting for nodule size, the malignancy rates
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for part-solid, solid and pGGN were 63 %, 32 % and 13 %,
respectively [25].
An increase in pulmonary nodule attenuation at
LCDT follow-up, the development or increment of a
solid component within the pulmonary nodule should
raise suspicions of malignancy, even if the nodule size
is stable (Figs. 2 and 3).
The pulmonary nodule size is another important predictor
for malignancy in heavy smokers, as good evidence exists for
a strong correlation between nodule size and risk of malignan-
cy [28, 29]: in a meta-analysis of eight CT screening trials, the
prevalence of malignancy depended on nodule size, ranging
from 0 % to 1 % for nodules <5 mm, from 6 % to 28 % for
those between 5 and 10 mm, and from 64 % to 82 % for
nodules > 20 mm [30]. A recent study by Horeweg et al.
[31] reported the probability of developing lung cancer in
participants from the Dutch–Belgian Lung Cancer Screening
(NELSON) trial. The authors found that participants with a
nodule smaller than 5 mm had a very low risk (0.6 %) of
developing lung cancer during 2 years of follow-up.
Unusual presentations of lung cancer
Besides the typical presentation of lung cancer, e.g. pulmo-
nary nodule, there is a wide spectrum of focal abnormalities
seen on low-dose CT that could not truly be defined as a
pulmonary nodules but, nevertheless, are early presentations
of primary lung cancer. These kinds of abnormalities, which
are unusual forms compared to pulmonary nodules, include
cancers associated with ‘cystic airspaces’ or ‘non-nodular’
cancers presenting, for example, as fibrotic changes or scar-
like lesions. Such focal abnormalities are initial signs of lung
cancer which usually develop over time in a lung nodule or
Fig. 1 Primary lung adenocarcinomas. Radiological features of
pulmonary nodules according to their attenuation. (a) A low-dose CT
thin-section shows a 15-mm non-solid nodule (pure ground-glass
attenuation) of the right upper lobe: the nodule density is slightly higher
than that of normal lung parenchyma, and vessels are visualized within
the nodule (arrows). (b) Low-dose CT scan shows a 25-mm part-solid
nodule of the right lower lobe. This nodule is characterized by a 3-mm
central solid component (arrowhead) surrounded by a pure ground-glass
opacity. The vessels and a small peripheral airway (arrow) can be clearly
depicted within the ground-glass opacity. (c) Axial low-dose CT scan
shows a 12-mm subpleural solid nodule of the left upper lobe. The spec-
trum of early stage lung cancer presentation at low-dose CT includes solid
nodules as well as part-solid nodules and ground-glass nodules
Fig. 2 Increased attenuation of a small lung adenocarcinoma over 3
years in a 62-year-old man. (a) Low-dose CT image show a 5-mm non-
solid nodule of the upper left lobe (arrow). (b) Follow-up CT obtained 1
year later show a minimum increment of axial diameter and a slight
increase of nodule attenuation. (c) Two years later the progression to a
part-solid nodule is obvious. The development of a central solid
component (arrowhead) within the nodule can be observed. An
increase in pulmonary nodule attenuation at LCDT follow-up, the
development or increment of a solid component within the pulmonary
nodule should raise suspicions of malignancy, even if the nodule size is
stable. Typically, this appearance is suggestive of a peripheral lung
adenocarcinoma
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suspicious pulmonary opacities and, therefore, should be
checked at follow-up or annual repeat LDCT.
There is increasing evidence that early stage lung cancer
could arise from pre-existing pulmonary ‘cystic airspaces’
[32–35], including in this description all findings associated
with air spaces, such as cysts, bullae, and blebs.
These cancers associated with cystic airspaces have recent-
ly been described in a lung cancer screening program [36]: out
of 26 lung cancers identified abutting or in the wall of a cystic
airspace, 13were identified at baseline (13/595, 2%) and 13 at
annual screening (13/111, 12 %), which was significant (p <
0.0001). In a recent analysis aimed at evaluating findings of
22 interval and post-screen carcinomas in lung cancer screen-
ing, the authors showed that 22 % (5/22) of missed cancers
presented as bulla wall thickening on LDCT [37, 38].
This kind of presentation is usually slow growing on serial
low-dose CT scans [26] and the diagnosis of lung cancer is
suggested by the circumferential wall thickening of the cystic
airspaces or by the arising of a nodule along the wall of the
cystic airspaces (Fig. 4). Nevertheless, with tumor growth,
airspaces size could increase, decrease or remain unchanged
[35].
Lung cancer presenting as fibrotic changes or as scar-
like lesions are less common but could be encountered in
LDCT screening (Fig. 5). In a recent article aimed at
evaluating the early features of incident lung cancers de-
tected with LDCT [39], a remarkable percentage (7/17, 41
%) of cancers which exhibited an initial ‘non-nodular’
shape were observed. Similarly, Xu et al. [40] reviewed
the images of patients with diagnoses of lung cancer in
annual repeat rounds of CT screening and showed that
some cancers were recognized at previous LDCT scans
but they were considered to represent benign rather than
malignant findings. In that study, the cancers were
misclassified as fibrosis, scarring, and a simple bulla,
which the authors attributed to a lack of experience in
Fig. 3 Progression at the 1-year interval of a non-solid nodule in a 66-
year-old woman. (a) Low-dose CT section shows a 12-mm nodule with
ground-glass attenuation of the upper left lobe (arrow). (b) CT scan
obtained at annual repeat LDCT demonstrates a substantial stability in
size but with increased density, that indicates an increased risk for
malignancy. The lesion was surgically removed with a diagnosis of lung
adenocarcinoma. Sub-solid nodules that show an increment in attenuation
should be considered suspicious for malignancy
Fig. 4 Progressive changes of a lung adenocarcinoma associated with a
cystic airspace in a 60-year-old woman. (a) Axial low-dose CT shows an
8-mm cystic airspace with thin irregular non-solid wall in the upper left
lobe (arrow). (b) One year later the lesion has increased in size to 12 mm
and 2 years later, (c) a consistent irregular thickening with the
development of solid components along the wall was evident
(arrowhead). The histologic diagnosis was lung adenocarcinoma. This
kind of presentation is usually slow growing on serial low-dose CT scans
and the diagnosis of lung cancer is suggested by the circumferential wall
thickening of the cystic airspaces; with tumor growth, airspaces size could
increase, decrease or remain unchanged
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identifying findings suspicious for small lung cancers or
identifying small cancer with an unusual appearance.
Lung cancer growth
One of the advantages in lung cancer screening is the avail-
ability of serial annual LDCTscans, permitting comparison of
early changes of suspicious findings.
The growth rate of CT screen-detected lung cancer is often
unpredictable, with many characteristics such as size, mor-
phology, and attenuation that should be taken into account
managing suspicious lung nodules. Early lung cancers could
present various behaviours at LDCT follow-up, ranging from
very slow growth to rapidly growing cancers.
Growth rate can be difficult to estimate and volumetric
analyses of pulmonary nodules has been suggested as a pre-
cise tool for nodule size measurement and an accurate method
for assessing nodule growth. In the NELSON trial, solid
intraparenchymal nodules were measured by volumetric soft-
ware and with semi-automated measurements, the interob-
server agreement was excellent: identical volumes were mea-
sured by both observers in 89 % of nodules. However, in a
minority (approximately 11 %) of small solid nodules,
semiautomated measurements were not completely reproduc-
ible and, thus, may cause errors in the assessment of nodule
growth. Themost frequent cause of variability was incomplete
segmentation performed by the software due to an irregular
shape or irregular margins of the nodule. For this reason, for
small or irregularly shaped nodules, an observer should check
the segmentation shown by the program before accepting the
semiautomated volume measurement and drawing conclu-
sions about growth or stability of a nodule [41].
Obviously, the behaviours of screen-detected lung cancer is
strongly related to its histology: small cells and squamous cell
lung cancers are usually more aggressive forms compared to
adenocarcinomas which have a wide range of growth but are
usually slower [42].
Tipically, early lung cancer presenting as non-solid nodules
(ground-glass nodules, GGN) are slow-growing forms. Such
cancers, even if nodule size is determinant, could have such
indolent behaviours that short-term LDCT follow-up (e.g. 3
months) could be insufficient to determinate the real growth,
and longer follow-ups (e.g. up to 3 years) are desirable to
assess nodule growth (Fig. 6) [26]. When growth is very slow
and previous LDCT scans are available, it is necessary to
make annual comparisons with the oldest LDCT scan avail-
able to carefully note slight changes over time.
Part-solid nodules, especially those in which the solid com-
ponent is larger than 5 mm, should be considered malignant
until proven otherwise, provided either growth or no change is
Fig. 5 Low-dose CT images
show both an increase in size and
density of a scar-like lesion of the
left lung apex, consisting of a lung
adenocarcinoma. (a, c) Axial and
coronal LDCT sections of the left
apex show an irregular subpleural
opacity that was interpreted as
apical fibrotic changes. (b, d)
LDCT repeated at a 1-year
interval shows spiculations
(arrowhead) and a significant
thickening of the lesion (arrow).
A PET/CT scan was positive and
the patient went to lobectomy
with histologic diagnosis of
adenocarcinoma. Lung cancers
presenting as fibrotic changes or
as scar-like lesions are relatively
uncommon but could be
encountered in LDCT screening
Insights Imaging (2016) 7:449–459 453
seen at the 3-month LDCT follow-up . For these complex
lesions, the growth of the solid portion is more important
and reliable in assessing the malignancy of the nodule (Fig. 2).
Solid nodules have a wide range of growth but usually
present faster growth compared to subsolid nodules [43, 44]
(Fig. 7).
It is also important to consider that care should be taken not
to assume that all lesions that partially decrease in size at
short-term LDCT follow-up are necessarily benign. It is doc-
umented that adenocarcinomas can decrease temporarily in
size after antibiotic therapy, owing to fibrosis or atelectasis
[26]; in this case, a further LDCT scan is suggested to assess
the complete resolution or stability of the findings and to avoid
missed diagnosis (Fig. 8).
LDCT: lesion location and cancer detection
The detection of lung cancer with low-dose CT may be hin-
dered by the absence of intravenous contrast medium and the
low signal-to-noise ratio. As a consequence, endobronchial
lesions, pulmonary-hilum lung cancers, and parenchymal ab-
normalities at lung apices or within lung fibroses are difficult
to recognize, raising the potential for missed cancers.
Even if small lung cancer detected by screening are more
frequently localised in peripheral lung areas, nevertheless, a
small amount of lung cancers are also centrally located or
endobronchial.
The majority of screen-detected lung cancers are localised
in the periphery of the lungs, represented by the large amount
of adenocarcinomas more often localised peripherally [31],
while squamous cell and small cell carcinomas are most com-
mon centrally. A retrospective study performed by Lindell and
colleagues [45] showed that squamous cell and small cell
carcinomas represented 71 % and 88 %, respectively, of cen-
tral lung lesions (11 % of cancers detected).
Compared to peripherally located carcinomas, such lung
cancers could be difficult to detect because low-dose CT
images are unenhanced scans and possibly because screen-
ing a population at this location is far less common. In a
recent publication by Scholten and colleagues [46] focused
on missed lung cancer in the NELSON screening trial, the
authors showed that more than one-third of the 22 missed
cancers were endobronchial lesions (5/22) or mediastinal/
hilar lymph nodes (3/22). A dedicated evaluation of
endobronchial and hilar regions, with the use of coronal
MPR and both lung and mediastinal window settings, is,
Fig. 6 Slow-growing lung adenocarcinoma in a 61-year-old man. (a)
Low-dose CT axial section in the right upper lobe shows a 6-mm
ground-glass nodule (arrow). (b) Low-dose CT scan after 2 years
shows an increase in size of the nodule to 10 mm (arrow). (c) After 4
years from the first low-dose CT scan, the nodule showed the same
ground-glass attenuation but a progressive increase in size from 10 to
14 mm (arrow). Typically, early lung cancer presenting as non-solid
nodules are slow-growing forms
Fig. 7 Fast-growing lung
adenocarcinoma in a 79-year-old
man. (a) Axial LDCT image of
the chest shows a 7-mm sub-
pleural solid nodule in the left
upper lobe (arrow). (b) LDCT
scan obtained at 1-year interval
shows a rapid growth of the lesion
into a 23-mm solid nodule
(arrow) with an aggressive
behavior documented by the
concomitant enlargement of hylar
lymph nodes (arrowheads)
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therefore, suggested to minimize detection errors in lung
cancer screening (Figs. 9 and 10). Furthermore,
endobronchial and central lesions are mostly represented
by fast-growing or fast-progressing tumors such as squa-
mous cell carcinomas and small cell carcinomas [47] with
a usual VDT shorter than adenocarcinoma’s [48], making
the early diagnose of these lesions a worthy challenge, as
these rapidly growing missed cancers have the potential to
affect patient prognoses.
Additional lung regions that deserve specific consideration
in lung cancer screening are the lung apices. The detection and
interpretation of parenchymal abnormalities within lung api-
ces could be a challenge in lung cancer screening, as apical
regions are a frequent location of fibrotic scars and differential
diagnosis between lung cancer and fibrotic changes could be
complicated. Indeed, as reported by Scholten and colleagues
[46], an apical scar-like nodule was identified as a cause of a
missed lung cancer due to an interpretation error. Similarly,
Fig. 8 Transient decrease in size of a squamous cell lung cancer in a 74-
year-old man. (a) Unenhanced axial LDCT image of the chest shows a
solid nodule in the upper right lobe with an irregular shape and a
maximum diameter of 19 mm. (b) Follow-up LDCT scan obtained 1
month after antibiotic therapy demonstrated a significant regression of
the lesion. (c) At LDCT obtained 3 months later, the nodule grew in size
again. Biopsy was performed, and results of histology revealed lung
adenocarcinoma. It is reported that adenocarcinomas can show a transient
decrease in size, maybe related to fibrosis or atelectasis. In this cases, a
further LDCT scan is suggested to assess the complete resolution or
stability of the findings and to avoid missed diagnosis
Fig. 9 Lung cancer of the left
hylum in a 67-year-old man with
history of sarcoidosis. (a) Axial
low-dose CT image through lung
hyla does not show any
significant findings at baseline CT
screening. (b) Low-dose CT
image obtained at the same level 1
year later shows the appearance of
a 6-mm pulmonary nodule
(arrow) surrounded by vascular
and airways structures of the left
hylum. This finding without
contrast material injection can be
misinterpreted as a pulmonary
vessel. (c) The following year, the
low-dose CT scan reveals the
presence of a large lesion of the
left hylum (arrows) that was
characterize by increased
metabolic activity via PET scan
(d). The histological diagnosis
was a T2N1 squamous cell
carcinoma
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Diederich and colleagues [49] reported one nodule interpreted
as an apical scar at initial LDCT that showed slow growth
after 24 months was revealed to be lung adenocarcinoma.
Lung cancer diagnosis should, therefore, be taken into ac-
count when a new lesion arises in a previously detected apical
scar or when a focal apical abnormality shows progressive
enlargement at annual repeat low-dose CT scans. Any change
over time within an apical scarring should be carefully evalu-
ated to detect potential lung cancer (Fig. 11).
The detection of lung cancer could also be affected by the
location of the lesion when arising within previous lung abnor-
malities, such as interstitial lung disease. Sverzellati and
colleagues [50] showed that important abnormalities consistent
with fibrotic interstitial lung disease may be encountered in par-
ticipants in a lung cancer screening trial, with the crude preva-
lence of usual interstitial pneumonia/other chronic interstitial
pneumonia (UIP/OCIP) of 4.0 % (95 % CI 2.8–5.9%). In the
NELSON Screening trial, signs of pulmonary fibrosis were re-
ported in 117 (8 %) out of 1409 cases [51]. The presence of
radiological signs of interstitial lung disease could delay the di-
agnosis of early stage lung cancer as tumors can be hidden or
overlooked in the presence of underlying lung abnormalities
(Fig. 12). This is even more important if we consider that idio-
pathic pulmonary fibrosis is associated with an increased risk of
Fig. 10 Endobronchial lung
cancer. (a) Axial low-dose CT
shows a small lesion abutting the
posterior wall of the right main
bronchus, interpreted as non-
suspicious bronchial mucus
(arrow). (b) Low-dose CT
performed 1 year later shows a
significant reduction of bronchial
caliber due to the presence of
neoplastic tissue (arrowheads)
Fig. 11 Right apical lung cancer in a 71-year-old man. (a) Low-dose
axial CT scan shows small irregular fibrotic changes of the right apex
(arrow). (b) One year later, LDCT shows a slight increment of the focal
abnormalities with the typical aspect of apical fibrotic changes, with a
pleural tag and concomitant emphysema (arrow). (c) Two years later, a
remarkable increment in size was clearly depicted (arrow) and the lesion
has been surgically removed with a diagnosis of lung adenocarcinoma
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lung cancer [52] and some studies reported that the tumors pref-
erentially occurred in areas with lung fibrosis [53, 54].
Conclusion
There is a wide spectrum of low-dose CT findings in lung
cancer screenings. Awareness of the various radiological fea-
tures of early lung cancers and the familiarity with the low-
dose CT technique can improve the CT screening effective-
ness and avoid missed diagnosis.
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